U.S. District Judge Edward J. Davila ruled on March 30, 2026, that the case against the medical device manufacturer and its top executives may proceed. The litigation centers on claims that between September 2020 and August 2024, leadership incorrectly labeled the TabloCart as a non-medical accessory to avoid regulatory scrutiny. Plaintiffs further allege that the company artificially inflated demand figures for its dialysis machines while suppressing the reality of weakening sales.

The legal pressure intensified following the company's second-quarter 2024 earnings report, which triggered a 68% collapse in share price once the alleged misstatements were disclosed. Schubert Jonckheer & Kolbe LLP is now investigating potential breaches of fiduciary duty by directors and officers. The firm notes that the court found sufficient evidence of scienter—an intent to deceive—to allow the case to move forward, casting a shadow over the $50 million in insider stock sales executed during the period of the alleged deception.